Urinary podocyte excretion and proteinuria in patients treated with antivascular endothelial growth factor therapy for solid tumor malignancies.

Oncology 2014 4;86(5-6):271-8. Epub 2014 Jun 4.

Division of Hematology, Mayo Clinic, Rochester, Minn., USA.

Background: Urinary podocyte excretion (podocyturia) may function as a more specific marker of ongoing glomerular damage. This study sought to analyze the relationship between proteinuria and podocyturia in cancer patients treated with antivascular endothelial growth factor (anti-VEGF) agents.

Methods: Thirty-seven patients treated with anti-VEGF medications were analyzed in a single-institution, cross-sectional study. Podocyte cultures were performed on random urine collections (50-100 ml), and podocytes were identified by positive podocin staining. The corresponding urine samples were analyzed for protein and creatinine (Cr) measurements.

Results: Proteinuria ≥0.5 g/g Cr was found in 30% of the patients (median, 0.12; interquartile range, 0.04-0.86), and 62% had podocyturia. There was a significant difference in the amount of podocyturia between patients with proteinuria ≥0.5 g/g Cr and those with a value <0.5 g/g Cr (median podocyturia, 1.08 cells/mg Cr, range, 0-14.55 vs. 0.03 cells/mg Cr, range, 0-1.64, respectively; p < 0.001). A statistically significant correlation was observed between the cumulative dose of bevacizumab and both proteinuria (r = 0.48, p = 0.004) and podocyturia (r = 0.34, p = 0.045) as well as between proteinuria and podocyturia (r = 0.63, p < 0.001), suggesting that these are mechanistically related.

Discussion: Ongoing podocyte loss may be mechanistically related to the onset and severity of proteinuria in patients treated with anti-VEGF agents.

Download full-text PDF

Source
https://www.karger.com/Article/FullText/360180
Publisher Site
http://dx.doi.org/10.1159/000360180DOI Listing
September 2014
12 Reads

Publication Analysis

Top Keywords

patients treated
12
treated antivascular
8
antivascular endothelial
8
≥05 g/g
8
proteinuria ≥05
8
growth factor
8
endothelial growth
8
urinary podocyte
8
podocyte excretion
8
patients
5
random urine
4
cancer patients
4
performed random
4
urine collections
4
collections 50-100
4
positive podocin
4
identified positive
4
podocytes identified
4
50-100 podocytes
4
cultures performed
4

References

(Supplied by CrossRef)

Granger JP et al.
Hypertension 2009

Maharaj A et al.
Microvasc Res 2007

Daniels BS et al.
Am J Nephrol 1993

Barisoni L et al.
Am J Nephrol 2003

Kennedy C et al.
J Am Soc Nephrol 2010

Qiu Y et al.
J Am Soc Nephrol 2010

Parikh SM et al.
J Am Soc Nephrol 2010

Gurevich F et al.
Am J Med 2009

Launay-Vacher V et al.
Anticancer Drugs 2009

Similar Publications